Remec Ziga I, Groselj Urh, Drole Torkar Ana, Zerjav Tansek Mojca, Cuk Vanja, Perko Dasa, Ulaga Blanka, Lipovec Neza, Debeljak Marusa, Kovac Jernej, Battelino Tadej, Repic Lampret Barbka
Clinical Institute for Special Laboratory Diagnostics, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Department of Endocrinology, Diabetes and Metabolic Diseases, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Front Genet. 2021 Apr 27;12:648493. doi: 10.3389/fgene.2021.648493. eCollection 2021.
Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD) is a rare autosomal recessive disorder of fatty acid metabolism with a variable presentation. The aim of this study was to describe five patients with VLCADD diagnosed through the pilot study and expanded newborn screening (NBS) program that started in 2018 in Slovenia. Four patients were diagnosed through the expanded NBS program with tandem mass spectrometry; one patient was previously diagnosed in a pilot study preceding the NBS implementation. Confirmatory testing consisted of acylcarnitines analysis in dried blood spots, organic acids profiling in urine, genetic analysis of gene, and enzyme activity determination in lymphocytes or fibroblasts. Four newborns with specific elevation of acylcarnitines diagnostic for VLCADD and disease-specific acylcarnitines ratios (C14:1, C14, C14:2, C14:1/C2, C14:1/C16) were confirmed with genetic testing: all were compound heterozygotes, two of them had one previously unreported gene variant each (NM_000018.3) c.1538C > G; (NP_000009) p.(Ala513Gly) and c.661A > G; p.(Ser221Gly), respectively. In addition, one patient diagnosed in the pilot study also had a specific elevation of acylcarnitines. Subsequent genetic analysis confirmed compound heterozygosity. In agreement with the diagnosis, enzyme activity was reduced in five patients tested. In seven other newborns with positive screening results, only single allele variants were found in the gene, so the diagnosis was not confirmed. Among these, two variants were novel, c.416T > C and c.1046C > A, respectively (p.Leu139Pro and p.Ala349Glu). In the first 2 years of the expanded NBS program in Slovenia altogether 30,000 newborns were screened. We diagnosed four cases of VLCADD. The estimated VLCADD incidence was 1:7,500 which was much higher than that of the medium-chain acyl-CoA dehydrogenase deficiency (MCADD) cases in the same period. Our study also provided one of the first descriptions of variants in Central-Southeastern Europe and reported on 4 novel variants.
极长链酰基辅酶A脱氢酶缺乏症(VLCADD)是一种罕见的常染色体隐性脂肪酸代谢紊乱疾病,临床表现多样。本研究旨在描述通过2018年在斯洛文尼亚启动的试点研究和扩大新生儿筛查(NBS)项目确诊的5例VLCADD患者。4例患者通过串联质谱法在扩大的NBS项目中被确诊;1例患者此前在NBS实施前的试点研究中被确诊。确诊检测包括干血斑中的酰基肉碱分析、尿液中的有机酸谱分析、基因的遗传分析以及淋巴细胞或成纤维细胞中的酶活性测定。4例酰基肉碱特异性升高且具有VLCADD诊断特征性酰基肉碱比值(C14:1、C14、C14:2、C14:1/C2、C14:1/C16)的新生儿经基因检测确诊:均为复合杂合子,其中2例分别有一个此前未报道的基因变异(NM_000018.3)c.1538C>G;(NP_000009)p.(Ala513Gly)和c.661A>G;p.(Ser221Gly)。此外,1例在试点研究中确诊的患者酰基肉碱也有特异性升高。随后的基因分析证实为复合杂合子。与诊断结果一致,5例接受检测的患者酶活性降低。在其他7例筛查结果呈阳性的新生儿中,仅在该基因中发现单个等位基因变异,因此未确诊。其中,2个变异是新发现的,分别为c.416T>C和c.1046C>A(p.Leu139Pro和p.Ala349Glu)。在斯洛文尼亚扩大NBS项目的头2年里,共筛查了30000名新生儿。我们确诊了4例VLCADD。估计VLCADD发病率为1:7500,远高于同期中链酰基辅酶A脱氢酶缺乏症(MCADD)病例的发病率。我们的研究还首次描述了中东欧地区的变异情况,并报道了4个新变异。